2.0803
Schlusskurs vom Vortag:
$2.21
Offen:
$2.132
24-Stunden-Volumen:
23,867
Relative Volume:
0.11
Marktkapitalisierung:
$6.56M
Einnahmen:
$960.60K
Nettoeinkommen (Verlust:
$-7.10M
KGV:
-0.2752
EPS:
-7.56
Netto-Cashflow:
$-8.00M
1W Leistung:
-8.36%
1M Leistung:
-5.44%
6M Leistung:
-47.33%
1J Leistung:
-73.20%
Soligenix Inc Stock (SNGX) Company Profile
Firmenname
Soligenix Inc
Sektor
Branche
Telefon
609-538-8200
Adresse
29 EMMONS DRIVE, PRINCETON
Vergleichen Sie SNGX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
SNGX
Soligenix Inc
|
2.0803 | 6.56M | 960.60K | -7.10M | -8.00M | -7.56 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2020-07-28 | Herabstufung | Dawson James | Buy → Neutral |
2018-01-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2017-08-14 | Bestätigt | Maxim Group | Buy |
2017-07-17 | Eingeleitet | H.C. Wainwright | Buy |
Soligenix Inc Aktie (SNGX) Neueste Nachrichten
Zacks Small Cap Decreases Earnings Estimates for Soligenix - Defense World
Zacks Maintains $35.00 Price Per Share Valuation for Soligenix (NASDAQ: SNGX) Amid Promising Vaccine and CTCL Therapy Progress - Barchart.com
Q1 Earnings Forecast for Soligenix Issued By Zacks Small Cap - Defense World
SNGX: Preclinical Data Shows CiVax™ Booster Induces Broad Protection Against COVID-19… - Yahoo Finance
CiVax booster shows broad COVID-19 variant protection By Investing.com - Investing.com South Africa
IBN Initiates Coverage of Soligenix Inc. - GlobeNewswire
First National Financial Corporation to Host First Quarter Earnings Call on April 30, 2025 - The Globe and Mail
CiVax booster shows broad COVID-19 variant protection - Investing.com
Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants - PR Newswire
Soligenix Inc. (SNGX) reports earnings - Quartz
SOLIGENIX, INC. SEC 10-K Report - TradingView
Soligenix Trumps Year-End Financials - Baystreet.ca
Soligenix reports progress and 2024 financials By Investing.com - Investing.com Australia
Soligenix reports progress and 2024 financials - Investing.com India
Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results - Quantisnow
Soligenix Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Soligenix Financial Results Reveal Widening Losses While Clinical Pipeline Expands - StockTitan
Why Soligenix (NASDAQ: SNGX) Is ‘One to Watch’ - The Globe and Mail
Soligenix Inc expected to post a loss of 95 cents a shareEarnings Preview - TradingView
Soligenix (SNGX) Projected to Post Earnings on Friday - Defense World
Soligenix (NASDAQ: SNGX) Is ‘One to Watch’ - The Globe and Mail
Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’ - Financial Content
Soligenix (SNGX) Projected to Post Earnings on Thursday - Armenian Reporter
AllPennyStocks.com News: A Steady Stream of News and Developments Pushes Soligenix Near 52 Week High - ACCESS Newswire
Soligenix, Inc. (NASDAQ:SNGX) Sees Large Decrease in Short Interest - Defense World
HyBryte™ Treatment Studies Presented at Two Medical Conferences in March - Yahoo Finance
Soligenix (SNGX) Projected to Post Quarterly Earnings on Thursday - Defense World
BiomednewsbreaksSoligenix Inc. (SNGX) To Present Hybrytetm And SGX302 Data At Dermatology Conferences - MENAFN.COM
Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
Soligenix Aims To Push The Boundaries In Treating Rare Diseases - The Globe and Mail
Soligenix Advances Innovative Treatments for Rare Diseases - citybuzz -
TALTZ’s Rapid Market Ascent Reflects its Unparalleled Ability to Transform the Treatment Landscape for Autoimmune Diseases | DelveInsight - GlobeNewswire Inc.
Soligenix's Leadership Aims To Drive Growth In Rare Disease Markets In 2025 And 2026 - The Globe and Mail
Silicon Valley - Financial Content
SoundHound AI Stock at a Crossroads—Is a Bottom in Sight? - The Globe and Mail
Soligenix settles debt with Pontifax lenders - MSN
Soligenix, Inc. Repays and Terminates Loan Agreement with Pontifax Medison FinanceOn February 5, 2025, Soligenix, Inc. (NASDAQ:SNGX) announced in an SEC Filing the full repayment and termination of all outstanding obligations under the Loan and Se - Defense World
Soligenix Repays Loan, Boosting Financial Flexibility - TipRanks
Soligenix on Way to Bio Conference in NYC - Baystreet.ca
Rare Disease Pioneer Soligenix Takes Center Stage at Major Biotech Investor Summit - StockTitan
Symbol Lookup - GuruFocus.com
SPI Energy and Soligenix Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV - ACCESS Newswire
Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
Soligenix (NASDAQ:SNGX) & Rhythm Pharmaceuticals (NASDAQ:RYTM) Head to Head Contrast - Defense World
Soligenix (SNGX) Stock Price, News & Analysis - MarketBeat
Soligenix (NASDAQ: $SNGX) Unveils Two-Pronged Approach To Tackle Rare Diseases & Unmet Medical Needs - MSN
Finanzdaten der Soligenix Inc-Aktie (SNGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):